Tong Shuping, Revill Peter
Liver Research Center, Rhode Island Hospital, The Alpert Warren School of Medicine, Brown University, Providence, RI, USA; Key Laboratory of Medical Molecular Virology, Shanghai Medical College, Fudan University, Shanghai, China.
Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Doherty Institute, Melbourne, VIC, Australia.
J Hepatol. 2016 Apr;64(1 Suppl):S4-S16. doi: 10.1016/j.jhep.2016.01.027.
Chronic infection with hepatitis B virus (HBV) greatly increases the risk for liver cirrhosis and hepatocellular carcinoma (HCC). HBV isolates worldwide can be divided into ten genotypes. Moreover, the immune clearance phase selects for mutations in different parts of the viral genome. The outcome of HBV infection is shaped by the complex interplay of the mode of transmission, host genetic factors, viral genotype and adaptive mutations, as well as environmental factors. Core promoter mutations and mutations abolishing hepatitis B e antigen (HBeAg) expression have been implicated in acute liver failure, while genotypes B, C, subgenotype A1, core promoter mutations, preS deletions, C-terminal truncation of envelope proteins, and spliced pregenomic RNA are associated with HCC development. Our efforts to treat and prevent HBV infection are hampered by the emergence of drug resistant mutants and vaccine escape mutants. This paper provides an overview of the HBV life cycle, followed by review of HBV genotypes and mutants in terms of their biological properties and clinical significance.
慢性乙型肝炎病毒(HBV)感染会大大增加肝硬化和肝细胞癌(HCC)的风险。全球范围内的HBV分离株可分为十种基因型。此外,免疫清除阶段会选择病毒基因组不同部位的突变。HBV感染的结果受到传播方式、宿主遗传因素、病毒基因型和适应性突变以及环境因素之间复杂相互作用的影响。核心启动子突变和消除乙肝e抗原(HBeAg)表达的突变与急性肝衰竭有关,而基因型B、C、A1亚基因型、核心启动子突变、前S缺失、包膜蛋白C端截短以及剪接的前基因组RNA与HCC的发生有关。耐药突变体和疫苗逃逸突变体的出现阻碍了我们治疗和预防HBV感染的努力。本文首先概述了HBV的生命周期,随后就其生物学特性和临床意义对HBV基因型和突变体进行了综述。